Solventum (SOLV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Solventum

NYSE•Healthcare•Medical Instruments & Supplies

$87.53-1.30(-0.01%)After hours

Market Cap

$15.34B

P/E

10.7x

P/S

1.8x

P/B

3.2x

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

How this company scores

GoodMetricSide Score: 65/100

Strongest: Profitability (25/25); weakest: Cash & Earnings Quality (9/25).

Profitability25/25

Growth15/25

Balance Sheet & Red Flags16/25

Cash & Earnings Quality9/25

Strengths

Strong marginsHigh ROERising earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 10.7x5y range 7.7x – 34.8x

Currently near its 7-quarter median.

P/S · 1.8x5y range 1.3x – 1.8x

Currently near its 7-quarter median.

P/B · 3.2x5y range 2.2x – 4.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg -1.9x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $15.34B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $8.31B
Q. Revenue: $2.21B
TTM EBITDA: $2.58B
TTM Op. Income: $2.08B
Q. Op. Income: $181.00M
TTM Net Income: $1.43B
Q. Net Income: $92.00M
EPS: $0.53
Shares Out.: $172.70M

$8.31B in TTM revenue declined 0.9% YoY, reaching $2.21B last quarter. TTM EBITDA of $2.58B and TTM operating income of $2.08B show growth is flowing through to the bottom line. TTM net income of $1.43B means revenue is converting into profit. Over the past year, TTM revenue is down 1% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.2%
EBITDA Margin: 14.2%
Op. Margin: 8.2%
Net Margin: 4.2%

Op. margin of 8.2% is down 1.7% YoY — costs are rising relative to revenue. Net margin at 4.2% and gross margin of 58.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 17% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 10.7x
P/S Ratio: 1.8x
P/B Ratio: 3.2x

At 10.7x P/E, the stock trades below typical market levels. P/S of 1.8x and P/B of 3.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 69% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $14.24B
Cash: $403.00M
Long-Term Debt: $4.57B
Book Value: $4.80B
D/E Ratio: 1.0
Debt/EBITDA: 14.6

With $14.24B in assets and $4.57B in long-term debt, D/E is 1.0and book value is $4.80B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 56% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $227.00M
TTM Free Cash Flow: $-118.00M
FCF Margin: -1.4%
FCF / Net Income: -0.1

TTM FCF of $-118.00M on $227.00M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 180% — an improving trend.